Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
India Poised to Become an Innovation-Driven Pharma Powerhouse: CDSCO
As patents for several long-standing drugs expire globally, Indian manufacturers are preparing to compete in segments such as GLP-1 inhibitors and emerging biologic categories signalling a move toward more value-driven and innovation-focused growth.
- By Newsdesk
- New Delhi
- Nov 26, 2025
India is on track to transition from its reputation as the “pharmacy of the world” to a global centre for pharmaceutical innovation over the next five years, according to senior officials from the Central Drugs Standard Control Organization (CDSCO).
Speaking at the 18th edition of CPHI & PMEC India in Greater Noida, Dr. R. Chandrashekar, Joint Drugs Controller at CDSCO, highlighted a series of regulatory reforms aimed at accelerating research and development across the sector. These include faster approval mechanisms, reduced compliance burdens, and the decriminalisation of minor offences measures designed to create a more supportive ecosystem for innovation.
A major boost is also expected from two government-led funding initiatives: a ₹5,000-crore plan to support pharmaceutical R&D, and a separate ₹1,00,000-crore hospital financing programme intended to strengthen healthcare and research infrastructure.
The industry’s evolution is already visible. Beyond its stronghold in generics, India is rapidly expanding capabilities in biologics, biosimilars, peptides, complex generics, and next-generation therapies. Industry representatives at the event called for a shift in mindset, urging companies to pursue advanced therapeutics such as cell and gene therapies, improved drug-delivery systems, and high-value molecules expected to dominate future markets.
As patents for several long-standing drugs expire globally, Indian manufacturers are preparing to compete in segments such as GLP-1 inhibitors and emerging biologic categories signalling a move toward more value-driven and innovation-focused growth.
The Organization of Pharmaceutical Producers of India described this period as a pivotal moment for the sector. With stronger intellectual-property protections, improved regulatory agility, and a rising emphasis on patient-centric innovation, the country is positioned to make rapid strides.
Small and medium-sized enterprises, traditionally centred around generics, are also stepping into the innovation space with novel technologies and research-led products. Their growing participation reflects a broader shift within the industry from volume-driven manufacturing to knowledge-driven discovery.
With supportive policies, large-scale funding, and increasing industry readiness, India’s pharmaceutical sector appears set for a significant transformation. The coming years could redefine its global identity, positioning the nation not just as a major supplier of affordable drugs but as a competitive innovation-led pharma hub.